Growth, Motor, and Social Development in Breast- And Formula-Fed Infants of Metformin-Treated Women With Polycystic Ovary Syndrome

J Pediatr. 2006 May;148(5):628-632. doi: 10.1016/j.jpeds.2006.01.011.

Abstract

Objectives: To test the hypothesis that metformin during lactation versus formula feeding would have no adverse effects on infants' growth, motor-social development, or intercurrent illness.

Study design: Growth, motor-social development, and illness requiring a pediatrician visit were assessed in 61 nursing infants (21 male, 40 female) and 50 formula-fed infants (19 male, 31 female) born to 92 mothers with polycystic ovary syndrome (PCOS) taking a median of 2.55 g metformin per day throughout pregnancy and lactation.

Results: Within sex, at 3 and 6 months of age, weight, height, and motor-social development did not differ (p > or = .06) between breast- and formula-fed infants. No infants had retardation of growth, motor, or social development. Intercurrent illnesses did not differ.

Conclusions: Metformin during lactation appears to be safe and effective in the first 6 months of infancy.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Bottle Feeding
  • Breast Feeding*
  • Child Development
  • Female
  • Follow-Up Studies
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Infant Formula
  • Infant, Newborn / growth & development*
  • Male
  • Metformin / therapeutic use*
  • Polycystic Ovary Syndrome / drug therapy*
  • Pregnancy
  • Pregnancy Complications / drug therapy*
  • Prospective Studies

Substances

  • Hypoglycemic Agents
  • Metformin